Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.
2.

Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.

Allan G, Davis J, Dickins M, Gardner I, Jenkins T, Jones H, Webster R, Westgate H.

Xenobiotica. 2008 Jun;38(6):620-40. doi: 10.1080/00498250802069088 .

PMID:
18570162
3.
4.

The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.

Zhao P.

Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):151-64. Review.

PMID:
18330044
5.

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.

Grime KH, Bird J, Ferguson D, Riley RJ.

Eur J Pharm Sci. 2009 Feb 15;36(2-3):175-91. doi: 10.1016/j.ejps.2008.10.002. Epub 2008 Nov 1. Review.

PMID:
19013237
6.

In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation.

Takedomi S, Matsuo H, Yamano K, Ohtani H, Sawada Y.

J Pharm Pharmacol. 2001 May;53(5):643-51.

PMID:
11370704
7.

Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes.

Zhao P, Kunze KL, Lee CA.

Drug Metab Dispos. 2005 Jun;33(6):853-61. Epub 2005 Mar 2.

PMID:
15743977
8.

A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.

Shibata Y, Takahashi H, Chiba M, Ishii Y.

Drug Metab Pharmacokinet. 2008;23(5):328-39.

9.

In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats.

Sekiguchi N, Kato M, Takada M, Watanabe H, Higashida A, Sakai S, Ishigai M, Aso Y.

Xenobiotica. 2008 Apr;38(4):368-81. doi: 10.1080/00498250701851891 .

PMID:
18340562
10.

Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo.

Yeung JH, Chan SL, Or PM.

Food Chem Toxicol. 2006 Aug;44(8):1414-23. Epub 2006 Apr 25.

PMID:
16698161
11.

Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats.

Zhu Q, Liao J, Xie L, Wang GJ, Liu XD.

Xenobiotica. 2009 Apr;39(4):293-301. doi: 10.1080/00498250802709428.

PMID:
19350452
12.

Pharmacokinetic model for N-nitrosodimethylamine based on Michaelis-Menten constants determined with the isolated perfused rat liver.

Skipper PL, Tomera JF, Wishnok JS, Brunengraber H, Tannenbaum SR.

Cancer Res. 1983 Oct;43(10):4786-90.

13.

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.

De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA.

Drug Metab Dispos. 2007 Oct;35(10):1766-80. Epub 2007 Jul 9.

PMID:
17620347
14.
15.

Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model.

Poirier A, Lavé T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP, Funk C.

Drug Metab Dispos. 2008 Dec;36(12):2434-44. doi: 10.1124/dmd.108.020750. Epub 2008 Sep 22.

PMID:
18809732
16.

Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models.

Leahy DE.

Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):619-28. Review.

PMID:
16859409
17.

Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes.

Lee JH, Oh JM, Lee MG.

Arch Pharm Res. 2008 Aug;31(8):951-64. doi: 10.1007/s12272-001-1269-3. Epub 2008 Sep 12. Review.

PMID:
18787780
18.

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.

Venkatesh PR, Goh E, Zeng P, New LS, Xin L, Pasha MK, Sangthongpitag K, Yeo P, Kantharaj E.

Biol Pharm Bull. 2007 May;30(5):1021-4.

19.

An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.

Tonn GR, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, Floren LC, Kersey K, Berry K, Marcus AP, Wang X, Van Lengerich B, Medina JC, Pearson PG, Wong BK.

Drug Metab Dispos. 2009 Mar;37(3):502-13. doi: 10.1124/dmd.108.021931. Epub 2008 Dec 16.

PMID:
19088267
20.

Exploration of the African green monkey as a preclinical pharmacokinetic model: intravenous pharmacokinetic parameters.

Ward KW, Coon DJ, Magiera D, Bhadresa S, Nisbett E, Lawrence MS.

Drug Metab Dispos. 2008 Apr;36(4):715-20. doi: 10.1124/dmd.107.019315. Epub 2008 Jan 28.

PMID:
18227143

Supplemental Content

Support Center